Table 1.
Summary of CDI recurrence cost by study
| Study | Recurrence cost | May 2022 dollars | Cost perspectives |
|---|---|---|---|
| USA | |||
| McFarland et al.25 | $1914.00 | $3405.08 | Healthcare perspective; costs obtained from medical billing records and laboratory charges |
| Desai et al.22 | $9501.74 | $11 722.81 | Healthcare perspective; study used societal perspective however indirect costs (productivity loss) were excluded from present analysis |
| Rodrigues et al.21 | $34 104.00 | $41 049.68 | Payer perspective; most cost values obtained from Centers for Medicare and Medicaid Services, with hospitalization cost from Healthcare Cost Utilization Project Nationwide Inpatient Sample (all-payer hospitalization database) |
| Zilberberg et al.24, 2017 | $12 043.00 | $14 495.70 | Payer perspective; costs measured as Medicare payments |
| Zhang et al.23 | $10 580.00 | $12 476.42 | Healthcare perspective; total healthcare costs were calculated as amount paid by primary and secondary insurers and by patients (i.e. copayment and deductibles) across all claims |
| Luo et al.20 | $6826.00 | $7734.25 | Modified third-party payer’s perspective (included costs of medications, hospitalizations and any procedures) |
| Average USA cost | $15 147.32 | ||
| Canada | |||
| Wagner et al.15 | $8250.05 | $9961.71 | Public payer perspective |
| Levy et al.2 | $8157.89 | $9765.04 | Public payer perspective; study used a societal perspective however indirect costs were excluded from present analysis |
| Lapointe-Shaw et al.27 | Metronidazole: $5386.00 Vancomycin: $5929.00 |
Metronidazole:$6351.97 Vancomycin:$6692.35 |
Public payer perspective, only vancomycin pathway cost considered |
| Average Canada cost | $8806.37 |